[Comparison of the effect of short-term treatment with nifedipine and verapamil on blood pressure, plasma atrial natriuretic peptide (ANP) and cyclic guanosine monophosphate (cGMP) in patients with primary arterial hypertension I degree according to WHO].
The aim of the study was the comparison of the effect of seven day treatment with nifedipine (2 x 10 mg daily) and subsequently with verapamil (3 x 40 mg daily) on blood pressure, heart rate, plasma ANP, cGMP, renin activity (PRA), aldosterone (ALDO) concentrations in patients with primary hypertension. The material consisted of 12 untreated patients with primary arterial hypertension Io WHO. These results suggest that short-term treatment with nifedipine and subsequently with verapamil in patients with primary hypertension Io WHO not influence on plasma ANP, cGMP, PRA and ALDO in spite of blood pressure reduction and the changes in heart rate. It seems that ANP did not participate in hypotensive action of nifedipine and verapamil. No augmentation of urinary sodium excretion was found after short-term treatment with nifedipine or verapamil.
Widecka
K
K
Kliniki Endokrynologii i Chorób Przemiany Materii PAM, Szczecinie.
Marzecka
J
J
Goździk
J
J
Gruszczyńska
M
M
Ciechanowski
K
K
Czekalski
S
S
D000328:Adult; D000450:Aldosterone / Q000378:metabolism; D009320:Atrial Natriuretic Factor / Q000187:drug effects; D006152:Cyclic GMP / Q000378:metabolism; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000145:classification / Q000188:drug therapy* / Q000378:metabolism; D008297:Male; D009543:Nifedipine / Q000494:pharmacology / Q000627:therapeutic use*; D012083:Renin / Q000378:metabolism; D014700:Verapamil / Q000494:pharmacology / Q000627:therapeutic use*
D000450:Aldosterone; D009320:Atrial Natriuretic Factor; D014700:Verapamil; D012083:Renin; D006152:Cyclic GMP; D009543:Nifedipine
Porównanie wpływu krótkotrwałego leczenia nifedypina i werapamilem na ciśnienie tetnicze oraz stezenie przedsionkowego peptydu natriuretycznego (ANP) i cyklicznego guanozynomonofosforanu (cGMP) w osoczu chorych na pierwotne nadciśnienie tetnicze I stopnia wg WHO.